{"nctId":"NCT01210716","briefTitle":"Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device","startDateStruct":{"date":"2010-09"},"conditions":["Autoimmune Diseases","Renal Disorders","Hematologic Disorders","Oncologic Disorders"],"count":37,"armGroups":[{"label":"AMICUS Therapeutic plasma exchange, TPE","type":"EXPERIMENTAL","interventionNames":["Device: Therapeutic plasma exchange"]},{"label":"Spectra Therapeutic plasma exchange, TPE","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Therapeutic plasma exchange"]}],"interventions":[{"name":"Therapeutic plasma exchange","otherNames":["TPE"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Medically stable patients undergoing more than one TPE procedure who have provided signed informed consent prior to participation.\n2. A physician's prescription for TPE for various non-emergent conditions.\n3. Test and Control TPE procedures that would be expected to be completed within approximately five weeks.\n\nExclusion Criteria:\n\n1. Patients under 18 years old.\n2. Patients on an ACE inhibitor medication should discontinue use of this medication in accordance with institutional practices.\n3. Patients with altered mental status that would prohibit the giving and understanding of informed consent.\n4. Patients who have experienced a serious adverse event associated with the first TPE clinical study procedure.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure","description":"The calculation is based on the volume of plasma that was processed through the machine compared to the volume of patient plasma that was actually removed during the procedure.\n\nPlasma Efficiency = (plasma removed/plasma processed)\\*100","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Measured by Adverse Events During the TPE Procedure","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["Paresthesia","Dizzy/Light-Headed","Nausea","Fatigue","Infiltration"]}}}